Every 8-K that JATT II Acquisition Corp (JATT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JATT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JATT filings page.
JATT II Acquisition Corp signed a Business Combination Agreement with Talawar Tx Inc. and Talawar Merger Sub to create a Nasdaq-listed biotechnology company focused on bispecific antibodies for immunology and inflammatory diseases. Merger Sub will merge into JATT, which will become a wholly owned subsidiary of Talawar.
The deal is supported by an oversubscribed $225 million PIPE at $10.00 per share for 22.5 million Talawar common shares, alongside approximately $60 million in JATT’s trust, targeting about $285 million of cash at closing before costs and assuming no redemptions. Closing is conditioned on shareholder approvals, Nasdaq listing of Talawar stock, and a minimum Available Cash of $125,000,000. The combined company expects funding to carry lead asset TALA‑125 through a Phase 2b proof‑of‑concept readout in the second half of 2028.
JATT II Acquisition Corp, a Cayman Islands blank check company, has completed its initial public offering of 6,000,000 ordinary shares at $10.00 per share, raising gross proceeds of $60,000,000. Underwriters hold a 45‑day over-allotment option for up to 900,000 additional shares at $10.00 per share.
Simultaneously, the company sold 300,000 Private Placement Shares to JATT Ventures II L.P. at $10.00 per share, generating an additional $3,000,000. As of April 20, 2026, $60,000,000, including $1,800,000 of deferred underwriting fees, was placed in a Trust Account for the benefit of public shareholders.
The audited balance sheet shows total assets of $62,400,000, including $2,400,000 in cash and $60,000,000 in the Trust Account. All 6,000,000 public shares are classified as redeemable at $10.00 per share, and the company has 24 months from the IPO closing to complete a business combination.
JATT II Acquisition Corp completed its initial public offering of 6,000,000 ordinary shares at $10.00 per share, generating gross proceeds of $60,000,000. Underwriters have a 45-day option to buy up to 900,000 additional shares at the same price.
At the IPO closing, the sponsor bought 300,000 private placement shares at $10.00 each, adding $3,000,000. A total of $60,000,000 from the IPO and private placement was deposited into a U.S.-based trust account to fund a future business combination, subject to specified redemption and charter amendment conditions.
In connection with the IPO, the company appointed four independent directors, constituted its board committees, and adopted an amended and restated charter in the Cayman Islands. JATT II is a healthcare-focused special purpose acquisition company targeting biotechnology and life sciences businesses.